MC
ZVRA icon

Menta Capital’s Zevra Therapeutics ZVRA Stock Holding History

Menta Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,683
Closed -$109K – 777
2017
Q4 		$109K Sell
1,683
-56
-3% -$3.38K 0.02% 603
2017
Q3 		$103K Sell
1,739
-376
-18% -$20K 0.02% 726
2017
Q2 		$135K Sell
2,115
-438
-17% -$28.8K 0.02% 727
2017
Q1 		$200K Sell
2,553
-387
-13% -$23.5K 0.02% 754
2016
Q4 		$139K Hold
2,940
– – 0.01% 821
2016
Q3 		$211K Hold
2,940
– – 0.02% 728
2016
Q2 		$187K Buy
2,940
+2,227
+312% +$366K 0.03% 785
2016
Q1 		$165K Buy
713
+72
+11% +$17.4K 0.02% 835
2015
Q4 		$204K Buy
+641
New +$174K 0.03% 761

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
IG
ING Group Amsterdam, Netherlands $20.5B AUM 49.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Menta Capital's ZVRA Position: Q1 2018 in Review

Menta Capital sold out of Zevra Therapeutics (ZVRA) in Q1 2018, closing a stake of 1,683 shares — an estimated $109K sold.

Menta Capital first reported a position in ZVRA in Q4 2015 and held it in 9 quarters. The position peaked at $211K in Q3 2016. 34 funds tracked by Wall St. Rank hold ZVRA as of Q1 2018.

  • Menta Capital reported no remaining Zevra Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Menta Capital sold 1,683 Zevra Therapeutics shares in Q1 2018, an estimated $109K.
  • Menta Capital first reported a position in Zevra Therapeutics in Q4 2015 and held it in 9 quarters.
  • Menta Capital's Zevra Therapeutics position peaked at $211K in Q3 2016.
  • 34 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2018.

Based on Menta Capital's 13F filing for Q1 2018, filed 15 May 2018.